Logo

Altana Licenses Spotfire DecisionSite Software

Nov 01, 2004

NEW YORK, Nov. 1 (GenomeWeb News) - Spotfire today said that Altana Pharma has licensed its Spotfire DecisionSite software worldwide for research, lead discovery, and clinical safety in four separate labs.

The drug maker currently uses the software in functional genomics and lead discovery research, Spotfire said.

 

Altana will integrate DecisionSite into its research portal, and said it plans to use Spotfire's posters as a global reporting platform to "publish, share, and extend" DecisionSite analysis results across project teams.

Breaking News
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.